Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba TrialAnne Sophie Kubasch, Uwe Platzbecker, Fatiha Chermat et al.|Blood|2018Cited by 17
Disease-modifying activity of ruxolitinib in a patient with <i>JAK2</i>-negative CMML-2Silvan Francke, Uwe Platzbecker, Anna Mies et al.|Leukemia & lymphoma/Leukemia and lymphoma|2016Cited by 5
Impairment of the Stromal SDF-1-Mediated Hematopoietic Support By GDF-11 in MDS Is Rescued By LuspaterceptManja Wobus, Uwe Platzbecker, Martin Bornhäuser et al.|Blood|2018Cited by 0